[go: up one dir, main page]

WO2001074364A3 - A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease - Google Patents

A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease Download PDF

Info

Publication number
WO2001074364A3
WO2001074364A3 PCT/EP2001/003551 EP0103551W WO0174364A3 WO 2001074364 A3 WO2001074364 A3 WO 2001074364A3 EP 0103551 W EP0103551 W EP 0103551W WO 0174364 A3 WO0174364 A3 WO 0174364A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
galantamine
treatment
alzheimer
underlying cause
Prior art date
Application number
PCT/EP2001/003551
Other languages
French (fr)
Other versions
WO2001074364A2 (en
Inventor
Wim Louis Julien Parys
Michael Pontecorvo
Original Assignee
Janssen Pharmaceutica Nv
Wim Louis Julien Parys
Michael Pontecorvo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv, Wim Louis Julien Parys, Michael Pontecorvo filed Critical Janssen Pharmaceutica Nv
Priority to AU2001246518A priority Critical patent/AU2001246518A1/en
Priority to EP01919406A priority patent/EP1272190A2/en
Publication of WO2001074364A2 publication Critical patent/WO2001074364A2/en
Publication of WO2001074364A3 publication Critical patent/WO2001074364A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Galantamine has be used in the treatment of a number of chronic diseases. Galantamine has been found to be safe and effective in the treatment of Alzheimer's disease. The therapeutic drugs, including galantamine, that have been used to date for the treatment of Alzheimer's disease were thought to provide only symptomatic relief. It has now been shown that galantamine can be used for the treatment of the underlying cause of the disease.
PCT/EP2001/003551 2000-04-03 2001-03-28 A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease WO2001074364A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001246518A AU2001246518A1 (en) 2000-04-03 2001-03-28 A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease
EP01919406A EP1272190A2 (en) 2000-04-03 2001-03-28 A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19426200P 2000-04-03 2000-04-03
US60/194,262 2000-04-03

Publications (2)

Publication Number Publication Date
WO2001074364A2 WO2001074364A2 (en) 2001-10-11
WO2001074364A3 true WO2001074364A3 (en) 2002-05-16

Family

ID=22716910

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/003551 WO2001074364A2 (en) 2000-04-03 2001-03-28 A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease

Country Status (4)

Country Link
EP (1) EP1272190A2 (en)
AU (1) AU2001246518A1 (en)
CA (1) CA2310990A1 (en)
WO (1) WO2001074364A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2310926C (en) * 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
GB0329498D0 (en) 2003-12-19 2004-01-28 Novartis Ag Organic compounds
CA2986431C (en) * 2015-05-18 2020-04-14 Synaptec Development Llc Galantamine clearance of amyloid.beta.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
EP2311441A1 (en) 1998-11-23 2011-04-20 Bonnie M. Davis Dosage formulations for acetylcholinesterase inhibitors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRODATY H.: "Galanthamine.", DRUGS AND AGING, (1996) 9/1 (66-67)., XP001022490 *
NORDBERG, AGNETA ET AL: "Cholinesterase inhibitors in the treatment of Alzheimer 's disease: a comparison of tolerability and pharmacology", DRUG SAF. (1998), 19(6), 465-480, XP001037505 *
RAINER, M. ET AL: "Long-term cognitive benefit from galanthamine in Alzheimer 's disease", INT. J. GERIATR. PSYCHOPHARMACOL. ( 1998 ), 1(4), 197-201, XP001022883 *
See also references of EP1272190A2 *
THATTE, URMILLA: "Galantamine Sanochemia Pharmazeutika AG", CURR. OPIN. CENT. PERIPHER. NERV. SYST. INVEST. DRUGS ( 1999 ), 1(3), 357-372, XP001022937 *

Also Published As

Publication number Publication date
CA2310990A1 (en) 2000-10-09
EP1272190A2 (en) 2003-01-08
WO2001074364A2 (en) 2001-10-11
AU2001246518A1 (en) 2001-10-15

Similar Documents

Publication Publication Date Title
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
CA2431565A1 (en) Pharmaceutical compositions based on anticholinergics and ciclesonide
WO2001095899A8 (en) Pharmaceutical compositions comprising cannabidiol derivatives
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
EP1374875A3 (en) Pharmaceutical compositons comprising arsenic for the treatment of myelodysplastic syndrome
WO2002043652A3 (en) Anti-proliferative drugs
CA2503810A1 (en) Therapeutic agent for fibromyalgia
ZA200203156B (en) Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrindependent microcirculation disorders.
CA2245123A1 (en) Use of rosaceae plant extract as a bradykinin antagonist
CA2310950A1 (en) An efficacious dosage regiment of galantamine that reduces side effects
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
WO2000008007A3 (en) Cyclopentabenzofuran derivatives and their use
GB0020504D0 (en) Therapeutic method
EP0657167A3 (en) Use of oenotheine B for the manufacture of a medicament for the treatment of disorders related to hyperandrogenism, pharmaceutical compositions containing oenotheine B and a process for its preparation from epilobium parviflorum.
WO2001074339A3 (en) A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
WO2001074364A3 (en) A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease
IL147188A (en) Use of il6ril6 chimera for the manufacture of a medicament for neurological diseases
WO2001047533A3 (en) INHIBITION OF GSK-3$g(b)
EP1161948A3 (en) Pharmaceutical or food composition for treatment of brain edema
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
EP1161254A4 (en) Treatment of autoimmune diseases with american ginseng extract
MD2068G2 (en) Method of treatment of the Herpes simplex infection
WO2003066806A3 (en) Therapeutic use of aziridino compounds
MD2491F1 (en) Use of bromide of S-ethyl isothiouronium (isoturone) for algodysmenorrhea treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001919406

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001919406

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001919406

Country of ref document: EP